本文選題：光動力治療(PDT) + 膽管癌��； 參考：《第二軍醫(yī)大學(xué)》2015年碩士論文

【摘要】：目的：對于無法手術(shù)切除的膽管癌病人,光動力治療展現(xiàn)出了很好的應(yīng)用前景。我們的研究目的是評估YLG-I作為光敏劑在光動力治療中的有效性以及YLG-I介導(dǎo)的光動力治療合用Avastin是否能增益光動力治療在膽管癌細胞系FRH0201中的作用。方法：本研究以人膽管癌細胞系FRH0201為研究對象,在體外實驗中應(yīng)用新型光敏劑YLG-I對FRH0201進行光動力治療處理,652nm波長激發(fā)后,觀察細胞的生長情況,并通過CCK8實驗比較對照組、Avastin組、光動力治療組及光動力治療加Avastin組之間腫瘤細胞的生長抑制情況。體內(nèi)實驗中,建立裸鼠皮下移植瘤模型,實施光動力治療后比較對照組、Avastin組、光動力治療組及光動力治療加Avastin組之間裸鼠皮下腫瘤的生長情況。留取皮下移植瘤標(biāo)本,做免疫組織化學(xué)染色分析各組腫瘤組織內(nèi)VEGF的表達情況。結(jié)果：YLG-I介導(dǎo)的光動力治療組和YLG-I介導(dǎo)的光動力治療組合用Avastin組與空白對照組及單獨使用Avastin治療組比較在腫瘤治療效果上有著極為明顯的獲益。在合用Avastin治療組中可以觀察到血管內(nèi)皮生長因子的表達受到了明顯的抑制。結(jié)論：YLG-I作為光敏劑在光動力治療中的應(yīng)用有著很好的有效性,同時合用血管內(nèi)皮生長因子抑制劑以阻斷血管內(nèi)皮生長因子通路能夠減少VEGF的表達或許是增益光動力治療療效的有效途徑。
[Abstract]:Objective: photodynamic therapy is promising for cholangiocarcinoma patients who can not be resected surgically. Our aim was to evaluate the efficacy of YLG-I as a Guang Min agent in photodynamic therapy and whether YLG-I mediated photodynamic therapy combined with Avastin could enhance the role of photodynamic therapy in cholangiocarcinoma cell line FRH0201. Methods: in this study, the human cholangiocarcinoma cell line FRH0201 was studied. In vitro, a new Guang Min agent, YLG-I, was used to treat FRH0201 with photodynamic therapy at 652 nm wavelength. The growth of the cells was observed, and the control group was compared with the control group by CCK8 experiment. Growth inhibition of tumor cells between photodynamic therapy group and photodynamic therapy plus Avastin group. In vivo model of subcutaneous transplanted tumor was established in nude mice. After photodynamic therapy the growth of subcutaneous tumor in nude mice was compared among control group photodynamic therapy group photodynamic therapy group and photodynamic therapy plus Avastin group. The expression of VEGF in tumor tissues was analyzed by immunohistochemical staining. Results compared with the control group and the Avastin alone group, the Avastin group and the YLG-I mediated photodynamic therapy group were significantly beneficial in the treatment of tumor. The expression of vascular endothelial growth factor (VEGF) was significantly inhibited in Avastin treatment group. Conclusion as Guang Min, the application of WYLG-I in photodynamic therapy is very effective. At the same time, the combination of vascular endothelial growth factor inhibitor to block the vascular endothelial growth factor pathway can reduce the expression of VEGF may be an effective way to gain photodynamic therapy.
【學(xué)位授予單位】：第二軍醫(yī)大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2015
【分類號】：R735.8

【共引文獻】

相關(guān)期刊論文 前1條

1 陳青;白定群;;光化學(xué)轉(zhuǎn)染對腫瘤治療的研究進展[J];世界復(fù)合醫(yī)學(xué);2015年02期

相關(guān)博士學(xué)位論文 前2條

1 劉定陽;干細胞相關(guān)基因MSI在人腦膠質(zhì)瘤中的表達及功能研究[D];中南大學(xué);2013年

2 郝進敏;EIF3C在人腦膠質(zhì)瘤中的表達及其對腦膠質(zhì)瘤U87MG細胞增殖作用的體內(nèi)外研究[D];河北醫(yī)科大學(xué);2015年

相關(guān)碩士學(xué)位論文 前2條

1 張廣健;神經(jīng)電生理監(jiān)測對中央?yún)^(qū)膠質(zhì)瘤手術(shù)輔助間質(zhì)內(nèi)放化療的臨床研究[D];天津醫(yī)科大學(xué);2012年

2 蔡曉軍;激光免疫療法對小鼠H22肝癌的長期及系統(tǒng)抗腫瘤效應(yīng)研究[D];南方醫(yī)科大學(xué);2014年

，

本文編號：1859081